Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Morgan H. James, Jennifer E. Fragale, R. Nisha Aurora, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 5, pp. 717-719
Open Access | Times Cited: 51

Showing 26-50 of 51 citing articles:

Sleep disturbance in substance use disorders: the orexin (hypocretin) system as an emerging pharmacological target
Utsav Gyawali, Morgan H. James
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 228-229
Closed Access | Times Cited: 11
The sensation seeking trait confers a dormant susceptibility to addiction that is revealed by intermittent cocaine self-administration in rats
Shayna L. O’Connor, Gary Aston‐Jones, Morgan H. James
Neuropharmacology (2021) Vol. 195, pp. 108566-108566
Open Access | Times Cited: 13
Involvement of orexin-2 receptors in the CA1 region of the hippocampus in the extinction and reinstatement of methamphetamine-induced conditioned place preference in the rats
Haleh Amirteymori, Ali Veisi, Hossein Khaleghzadeh‐Ahangar, et al.
Peptides (2022) Vol. 160, pp. 170926-170926
Closed Access | Times Cited: 9
Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Glenn Pascasio, et al.
Neuropharmacology (2023) Vol. 239, pp. 109685-109685
Open Access | Times Cited: 5
Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity
Jazmine D. W. Yaeger, Kevin T. Krupp, Jason J. Gale, et al.
Medicine in Drug Discovery (2020) Vol. 8, pp. 100059-100059
Open Access | Times Cited: 14
The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment
Jennifer D. Ellis, Daniel C. Han, Jami L. Mayo, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 6, pp. 1408-1417
Closed Access | Times Cited: 1
The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl
Shayna L. O’Connor, Jennifer E. Fragale, Morgan H. James, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 12
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date
Reda Chalhoub, Peter W. Kalivas
Drugs (2020) Vol. 80, Iss. 15, pp. 1509-1524
Open Access | Times Cited: 12
Machine Learning Models to Predict Ligand Binding Affinity for the Orexin 1 Receptor
Vanessa Zhang, Shayna L. O’Connor, William J. Welsh, et al.
Artificial Intelligence Chemistry (2023) Vol. 2, Iss. 1, pp. 100040-100040
Open Access | Times Cited: 4
Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder
Augustus M White, Michelle Eglovitch, Anna Beth Parlier‐Ahmad, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0304461-e0304461
Open Access | Times Cited: 1
Emerging medications and pharmacological treatment approaches for substance use disorders
Joel S. Raymond, Anastasios Athanasopoulos, Connie J. Badolato, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 248, pp. 173952-173952
Open Access | Times Cited: 1
Potential therapeutic targets for the treatment of opioid abuse and pain
Norikazu Kiguchi, Mei‐Chuan Ko
Advances in pharmacology (2022), pp. 335-371
Closed Access | Times Cited: 7
Recent advances in drug discovery efforts targeting the sigma 1 receptor system: Implications for novel medications designed to reduce excessive drug and food seeking
L. Knowles, Abanoub J. Armanious, Youyi Peng, et al.
Addiction Neuroscience (2023) Vol. 8, pp. 100126-100126
Open Access | Times Cited: 2
Drug addiction co-morbidity with alcohol: Neurobiological insights
M. Adrienne McGinn, Caroline B. Pantazis, Brendan J. Tunstall, et al.
International review of neurobiology (2021), pp. 409-472
Closed Access | Times Cited: 5
Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target
Chung Jung Mun, Matthew J. Reid, Sarah Sarandos, et al.
Current Addiction Reports (2024)
Closed Access
Orexins in Food and Addiction
Morgan H. James, Gary Aston‐Jones
Oxford University Press eBooks (2024), pp. 157-164
Closed Access
An emerging multi-omic understanding of the genetics of opioid addiction
Eric O. Johnson, Heidi S. Fisher, Kyle A. Sullivan, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 20
Open Access
Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study
Heather E. Webber, Jessica C. Badawi, Douglas Calvillo, et al.
Journal of Addictive Diseases (2024), pp. 1-8
Closed Access
Repurposing of substances with lactone moiety for the treatment of γ-Hydroxybutyric acid and γ-Butyrolactone intoxication through modulating paraoxonase and PPARγ
Sepand Tehrani Fateh, Amir Salehi-Najafabadi
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 1
Les antagonistes doubles des recepteurs de l’orexine : une nouvelle approche pharmacologique du traitement de l’insomnie chronique
Régis Lopez
Médecine du Sommeil (2022) Vol. 19, Iss. 3, pp. 195-199
Open Access | Times Cited: 1
Opioid Effects on Sleep
Jennifer D. Ellis, Chung Jung Mun, Patrick H. Finan
Oxford University Press eBooks (2023), pp. 296-316
Closed Access
緩和的放射線治療とメサドンによるがん疼痛緩和後にオピオイド中止により離脱症状を呈した1例
Ayaka Ishikawa, Sayaka Arakawa, Hiroto Ishiki, et al.
Palliative Care Research (2023) Vol. 18, Iss. 3, pp. 159-163
Open Access
The Neurobiology of Opioid Use
Shailesh Khatri, Erin E. Maher, Emma O. Bondy, et al.
Oxford University Press eBooks (2023), pp. 139-171
Closed Access
Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects
Jasper Dingemanse, Pascal Charef, Jed Black, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 133, pp. 110955-110955
Open Access
The Orexin System, Prescription Opioid Use Disorder, and Orexin Receptors Blockade
Alessandra Matzeu, Rémi Martin‐Fardon
Springer eBooks (2022), pp. 1-17
Closed Access

Scroll to top